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zation of health services. The overall C/B ratio turned out
to be 1:6.52, in other words, compared to control group,
asthma education programs reduce direct medical costs by
$6.52 for each dollar spent in providing the education.
CONCLUSION: Our study shows that the asthma educa-
tion programs are beneficial in reducing the direct medical
costs associated with asthma. These findings suggest that
education programs benefit the patient and lead to their
well being which in turn will benefit both the patient and
the third-party payers.
PRD5
THE FIRST PHARMACOECONOMIC STUDY IN 
ASTHMA: SOME IMPORTANT OBSERVATIONS
Andersson F
Astra Draco AB, Lund, Sweden
Treatment options for control of asthma are numerous.
However, as for other diseases, there are often differences
between clinical trials and what takes place in clinical
practice. 
OBJECTIVES: To present some methodological issues in
relation to the first “real-life” pharmacoeconomics study
(PECT) in asthma, comparing the cost-effectiveness of
budesonide Turbuhaler versus sodium cromoglycate Spin-
haler for moderately asthmatic children, aged 5–11 years. 
METHODS: One hundred thirty-eight Swedish patients
were randomized to one of the two treatments. Patients
were then treated according to local clinical practice on
an open basis for 12 months. Thus, any additional ther-
apy was allowed, including switching to the comparator.
The objective was to reach the same degree of patient
asthma control in both groups. There were six scheduled
study visits. Efficacy (asthma control) and resource use
were recorded in patient diaries and case report forms. 
RESULTS: 1) A number of problems in relation to ran-
domization, such as center effects and sample selection
bias, were experienced. 2) A dilution of difference in effect
was experienced due to the fact that 36% of patients on
sodium cromoglycate had to switch to budesonide because
of poor control of asthma (as judged by the physician). 3)
Because there was insufficient data available on which to
base a power calculation, too few patients were recruited.
4) Due to large standard deviations and the problems
listed above, a significant advantage in budesonide costs
could only be identified when various background factors
were taken into account in a multiple regression analysis. 
CONCLUSIONS: A number of different methodological
problems compared to ordinary piggy-back economic
evaluations arise in PECTs. Careful consideration of de-
sign is necessary to ensure high-quality research. Innova-
tive methodological approaches, such as multiple regres-
sion analysis, are required.
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THE USE OF GENERALIZED ESTIMATING 
EQUATIONS IN LONGITUDINAL STUDIES OF 
RESOURCE UTILIZATION: THE CASE 
OF ASTHMA
Itzler RF1, Dasbach EJ1, Koch GG2, Heyse JF1
1Merck Research Laboratories, Blue Bell, PA, USA; 2University 
of North Carolina, Chapel Hill, NC, USA
OBJECTIVE: To evaluate the importance of accounting
for correlations between observations when analyzing re-
peated measures of healthcare utilization. 
METHODS: Poisson regression was applied with and with-
out generalized estimating equations to analyze -agonist
use, healthcare contacts, and nocturnal awakenings in
chronic asthmatics in two large similarly designed, 12-week,
randomized trials of Montelukast, a once daily leukotriene
receptor antagonist, compared to placebo. Data on -ago-
nist use and nocturnal awakenings were recorded on daily
diary cards. Healthcare contacts included visits to physi-
cians, the emergency room, and hospitalizations docu-
mented as not mandated by the protocols. 
RESULTS: Montelukast compared to placebo decreased
the rate of days of -agonist use by 9.6% (p  0.0001),
nights with awakenings by 22.5% (p  0.0001) and
healthcare contacts by 23.0% (p  0.09) when analyzed
without generalized estimating equations. Use of general-
ized estimating equations did not change the parameter
estimates for any of the health outcomes measured, but
did increase the standard errors and confidence intervals
in all cases. The increase in the standard errors ranged
from 19.1% to 355.1%. -agonist use and nights with
awakenings remained statistically significant. However,
healthcare contacts became less significant (p  0.16). 
CONCLUSION: Failure to account for correlations be-
tween observations may lead to erroneous conclusions
based on significance levels that are too small. In large
samples, exceeding 100–200 patients, generalized estimat-
ing equations provide one method of obtaining correct sig-
nificance levels and confidence intervals when data are
correlated. The example above included daily values for
12 weeks in 1300 patients. Other methods of adjusting for
correlated data are needed in smaller samples.
PRD8
A RETROSPECTIVE DATABASE STUDY OF 
PATIENT ADHERENCE WITH ASTHMA 
TREATMENT REGIMENS
Hutchison S, Beno C
PCS Health Systems, Inc., Outcomes Research Department, 
Scottsdale, AZ, USA
OBJECTIVES: Healthcare providers need accurate infor-
mation about all aspects of healthcare delivery. Clinical
trials provide useful information concerning the clinical
efficacy of treatment, but they are not representative of
the routine conditions with which patients must contend
when following treatment regimens. Database studies are
being used increasingly to provide information about pa-
tient adherence under routine conditions. 
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METHODS: A retrospective database study was con-
ducted to compare patient adherence and concomitant
oral steroid use among patients on oral 2 agonists or
leukotriene antagonist therapy. 
RESULTS: Consistent with our first hypothesis, patients
using antileukotrienes were more adherent than patients on
oral 2 agonists, over a 12-month period. However, con-
trary to our second hypothesis, patients using antileuko-
trienes were eight times more likely to be on concomitant
oral steroid therapy than patients using oral 2 agonists. 
CONCLUSIONS: These findings may reflect a “new
drug” effect: those patients whose disease is most diffi-
cult to control on existing therapies are placed on the
newest treatment, drug indications notwithstanding. Fi-
nally, the results of this study provide further evidence of
the utility of retrospective database studies to provide
healthcare providers with cost-effective information re-
flecting real-world patient behaviors.
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THE HEALTHCARE UTILIZATION OF PATIENTS 
WITH CHRONIC SINUSITIS
Edelman-Lewis B1, Lydick E2, Emani S1, Bentkover S1
1Fallon Clinic, Worcester, MA, USA; 2SmithKline Beecham 
Pharmaceuticals, Collegeville, PA, USA
The prevalence of sinusitis has been increasing, as has been
the number of visits for the condition. Relatively little data
are available on its diagnosis, treatment and costs. 
OBJECTIVE: The purpose of this study is to analyze re-
sources utilized in the treatment of sinusitis, in particular
recurrent sinusitis. 
METHODS: The database of Fallon Community Health
Plan (FCHP), a Massachusetts-based group model HMO,
was analyzed to identify members with three or more vis-
its for sinusitis in an eighteen month period. A total of
495 patients were identified. Their utilization of primary
care physician (PCP) and specialty visits, procedures, an-
cillary services, costs of services, type, quantity, and cost
of drugs prescribed was analyzed. 
RESULTS: Of the patients, 76% were women and 24%
were men. Age ranged between 18 years and 91 years
(mean  45). The subjects had a total of 17,407 proce-
dures and diagnoses during the study period. In 31% of
visits, the subjects were treated by a PCP; in 8.5% visits
they were seen by an Allergist; and in 6.7% visits they
were seen by an ENT. The most frequent primary diag-
nosis was Allergic rhinitis (8.2%) followed by acute si-
nusitis (5.8%). The total cost of the utilization was
$1,052,678 (mean  $2127). The total number of pre-
scriptions filled during the study period was 13,539
(mean  27.35). The total cost of these prescriptions was
$446,879 (mean  $903). 
CONCLUSION: The treatment and management of pa-
tients with chronic sinusitis is more intensive than com-
monly realized. The present study provides insight into
demographics and the type and costs of treatment of this
patient group.
PRD10
COST-EFFECTIVENESS OF AZITHROMYCIN 
AND CO-AMOXICLAV IN ACUTE SINUSITIS
Karpov O, Zaytsev A
Institute of Pharmacology, Saint-Petersburg, Russia
Azithromycin is an azalide antibiotic with broad-spec-
trum activity; it has a prolonged biological half-life and
slow elimination from nasal sinuses. These features make
it possible to use azithromycin during short-term periods
that may be important for compliance. However, the eco-
nomic results have not been investigated. 
OBJECTIVE: The purpose of this study was to evaluate
the efficacy, safety and cost of therapy of azithromycin
and a course of co-amoxiclav in acute sinusitis in adults. 
METHODS: Among 100 adults with acute sinusitis, 50
were randomized to receive azithromycin 500 mg once daily
for 3 days (group I), and 50 co-amoxiclav 625 mg tid for 10
days (group II). Clinical examination was performed at base-
line and 72 hours, 10–12 and 26–30 days after treatment ini-
tiation. Each sign and symptom was scored and clinical find-
ings were expressed by total clinical score (TCS). TCS was
significantly lower in group I after 72 hours following treat-
ment start and at 10–12 days. Cost analysis included drug
price, physician cost, and cost of hospitalization. 
RESULTS: At 10–12 days of therapy, 41 (82%) patients
in group I and only 26 (52%) in group II were free of
symptoms associated with increased duration and cost of
hospitalization. By the follow-up assessment, satisfactory
clinical response was indicated in both groups. The aver-
age cost of treatment for group I was $116 and in group II,
$150 per patient. During a half-year, relapse of sinusitis
was marked in 16% of cases in group II and the additional
treatment charges made on average $170 per patient. 
CONCLUSION: The treatment 3-day azithromycin is as
effective as 10-day co-amoxiclav, but azithromycin pro-
vides faster clinical effect and does not lead to relapse,
with better pharmacoeconomic outcomes.
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QUALITY OF LIFE ASSESSMENT IN ALLERGIC 
RHINITIS PATIENTS TREATED WITH 
LORATADINE
Hauser R, Smeeding J, Koeller J
University of Texas Center for Pharmacoeconomics, Austin, 
TX, USA
Allergic rhinitis can cause a severe decrease in a sufferer’s
quality of life. Many non-sedative antihistamines have
demonstrated efficacy in phase I through III trials. How-
ever, patients’ quality of life during treatment had not
been measured or evaluated. 
OBJECTIVE: The purpose of this study was to determine
if quality of life improves during a 3-week time period
while patients were being treated with loratadine for al-
lergic rhinitis. 
METHODS: Twenty-five patients with diagnosed aller-
gic rhinitis were treated with loratadine 10 mg every
